Abstract:Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most frequently mutated oncogene in human cancers with mutations predominantly occurring in codon 12. These mutations disrupt the normal function of KRAS by interfering with GTP hydrolysis and nucleotide exchange activity, making it prone to the GTP-bound active state, thus leading to sustained activation of downstream pathways. Despite decades of research, there has been no progress in the KRAS drug discovery until the groundbreaking discovery of covalently targeting the KRASG12C mutation in 2013, which led to revolutionary changes in KRAS-targeted therapy. So far, two small molecule inhibitors sotorasib and adagrasib targeting KRASG12C have received accelerated approval for the treatment of non-small cell lung cancer (NSCLC) harboring KRASG12C mutations. In recent years, rapid progress has been achieved in the KRAS-targeted therapy field, especially the exploration of KRASG12C covalent inhibitors in other KRASG12C-positive malignancies, novel KRAS inhibitors beyond KRASG12C mutation or pan-KRAS inhibitors, and approaches to indirectly targeting KRAS. In this review, we provide a comprehensive overview of the molecular and mutational characteristics of KRAS and summarize the development and current status of covalent inhibitors targeting the KRASG12C mutation. We also discuss emerging promising KRAS-targeted therapeutic strategies, with a focus on mutation-specific and direct pan-KRAS inhibitors and indirect KRAS inhibitors through targeting the RAS activation-associated proteins Src homology-2 domain-containing phosphatase 2 (SHP2) and son of sevenless homolog 1 (SOS1), and shed light on current challenges and opportunities for drug discovery in this field.

Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Combinatorial strategies to target RAS-driven cancers

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Targeting KRAS in cancer

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

KRAS-Degrading Compounds: A Novel Approach to Treat Cancer by Targeting Both Wild-Type and Mutated KRAS Forms

The current state of the art and future trends in RAS-targeted cancer therapies

RAS-targeted therapies: is the undruggable drugged?

Emerging strategies to target RAS signaling in human cancer therapy

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Eliminating oncogenic RAS: back to the future at the drawing board

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Rationale for RAS mutation-tailored therapies

Targeting KRAS: Crossroads of Signaling and Immune Inhibition

One Step Closer to Targeting RAS.

Targeting KRAS in Non-Small Cell Lung Cancer

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

From bench to bedside: current development and emerging trend of KRAS-targeted therapy